| Q39756815 | A Domain in the C-terminal region of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated Herpesvirus affects transcriptional activation and binding to nuclear heterochromatin |
| Q35973676 | A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP. |
| Q59621919 | AIDS-associated malignancies |
| Q22251046 | Aids-related malignancies |
| Q39793622 | An RNA Element in Human Interleukin 6 Confers Escape from Degradation by the Gammaherpesvirus SOX Protein |
| Q48333282 | Angiopoietin-2 is expressed in oral Kaposi's sarcoma |
| Q60263063 | Authors’ Reply to Verdelli et al.: There Is No Knowledge Without Experience |
| Q34092739 | Brd2/RING3 interacts with a chromatin-binding domain in the Kaposi's Sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (LANA-1) that is required for multiple functions of LANA-1. |
| Q59351570 | Contribution of the KSHV and EBV lytic cycles to tumourigenesis |
| Q36245115 | Corticosterone, inflammation, immune status and telomere length in frigatebird nestlings facing a severe herpesvirus infection |
| Q40163096 | Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence |
| Q33261811 | EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors |
| Q39631647 | Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas |
| Q34348453 | Functional dissection of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated herpesvirus involved in latent DNA replication and transcription of terminal repeats of the viral genome. |
| Q37865141 | Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients |
| Q35122236 | Genetic and molecular genetic studies in the diagnosis of immune-related lymphoproliferative disorders |
| Q90171225 | HHV-8-Associated Lymphoproliferative Disorders and Pathogenesis in an HIV-Positive Patient |
| Q34572946 | HIV-associated Kaposi sarcoma: pathogenic mechanisms |
| Q33760703 | Human herpesvirus-8 infection leads to expansion of the preimmune/natural effector B cell compartment |
| Q24646461 | Identification of a novel cellular transcriptional repressor interacting with the latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus |
| Q44403690 | Immunohistochemical study association between human herpesvirus 8 and multiple myeloma |
| Q36178610 | Inhibition of interleukin-6 expression by the V protein of parainfluenza virus 5 |
| Q42010475 | Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. |
| Q30433391 | KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation |
| Q50099317 | KSHV oral shedding and plasma viremia result in significant changes in the extracellular tumorigenic miRNA expression profile in individuals infected with the malaria parasite |
| Q37016504 | Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders |
| Q37593234 | Kaposi's Sarcoma-Associated Herpesvirus MicroRNAs Target GADD45B To Protect Infected Cells from Cell Cycle Arrest and Apoptosis |
| Q34841987 | Kaposi's Sarcoma-Associated Herpesvirus-Encoded LANA Down-Regulates IL-22R1 Expression through a Cis-Acting Element within the Promoter Region |
| Q73456324 | Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways |
| Q40173444 | Kaposi's sarcoma-associated herpesvirus induces sustained NF-kappaB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression |
| Q24534690 | Kaposi's sarcoma-associated herpesvirus induction of AP-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways |
| Q35077642 | Kaposi's sarcoma-associated herpesvirus infection of endothelial cells inhibits neutrophil recruitment through an interleukin-6-dependent mechanism: a new paradigm for viral immune evasion |
| Q35914351 | Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases |
| Q35785255 | Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1 |
| Q39892759 | Kaposi's sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis |
| Q40682995 | Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus functionally interacts with heterochromatin protein 1. |
| Q39992257 | Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. |
| Q89623336 | Microbes as Master Immunomodulators: Immunopathology, Cancer and Personalized Immunotherapies |
| Q34437977 | Mitotic chromosome-binding activity of latency-associated nuclear antigen 1 is required for DNA replication from terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus |
| Q36670930 | Molecular approaches towards characterization, monitoring and targeting of viral-associated hematological malignancies |
| Q33560572 | Molecular biology of KSHV in relation to AIDS-associated oncogenesis |
| Q35026060 | Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis |
| Q38863770 | Multicentric Castleman disease: Where are we now? |
| Q64974792 | Post-Liver Transplantation Multicentric Castleman Disease Treated with Valganciclovir and Weaning of Immunosuppression |
| Q42016255 | Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease |
| Q33282107 | Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA. |
| Q24538878 | Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes |
| Q36454456 | Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways |
| Q35964857 | Regulation of growth signalling and cell cycle by Kaposi's sarcoma-associated herpesvirus genes. |
| Q35124429 | Structure and function of latency-associated nuclear antigen |
| Q35104781 | The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3beta |
| Q33834414 | The latency-associated nuclear antigen of rhesus monkey rhadinovirus inhibits viral replication through repression of Orf50/Rta transcriptional activation |
| Q35196615 | The role of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression |
| Q42251072 | Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma |
| Q39683497 | Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic replication. |
| Q26740703 | Update and new approaches in the treatment of Castleman disease |
| Q37871527 | Viruses as key regulators of angiogenesis |